4/14/2022 7:21:00 AM
BeyondSpring Q4 Net Loss Attributable To The Co $9.5 Mln Vs $17.6 Mln Last Year
9/10/2021 7:29:53 AM
BeyondSpring Q2 Loss Per Share $0.46 Vs Loss $0.49 Last Year
6/4/2021 7:16:55 AM
BeyondSpring Doses First Patient In A Triple Combination Study With Plinabulin
5/24/2021 7:38:09 AM
BeyondSpring Announces Poster Presentation Of An Investigator-initiated Phase 1 Study
4/1/2021 12:19:35 AM
BeyondSpring Submits NDA To FDA And China NMPA For Plinabulin And G-CSF Combination For Chemotherapy-Induced Neutropenia